To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects

Multiple Myeloma Clinical Trial

Official title:

A Single Ascending Dose Pilot Study to Assess the Safety, Tolerability and Pharmacokinetics of NEX-20A Given as a Subcutaneous Prolonged-release Injection to Healthy Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05643248
• Other study ID #: NEX-20-01
• Status: Completed
• Phase: Early Phase 1
• Start date: November 28, 2022
• Est. completion date: September 26, 2023

Study information

• Verified date: October 2023
• Source: Nanexa AB
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-centre, single ascending dose (SAD) pilot study designed to evaluate the safety, tolerability, including local tolerability, and pharmacokinetics (PK) of NEX-20A (lenalidomide) after the administration of a single subcutaneous prolonged-release injection to healthy male volunteers

Description:

NEX-20A will be administered in sequential cohorts, 2 standard cohorts and an optional third cohort, each comprising 3 subjects. Subjects will be dosed in a sentinel fashion, and all available safety and tolerability data up until and including 10 days for the sentinel subjects must have been evaluated by the iSRC before dosing the remaining 2 subjects in each cohort.Once safety, tolerability and PK data of the last subject in each cohort has been collected, and interim data analysis has been conducted, there must be at least 1 week between dose escalations.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: September 26, 2023
• Est. primary completion date: September 26, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Willing and able to give written informed consent for participation in the study.

2. Healthy male subject aged 18 to 65 years, inclusive.

3. Clinically normal medical/surgical history, physical findings, vital signs, 12-lead electrocardiograms (ECGs) and safety laboratory values at the time of screening, as judged by the Investigator.

4. Prospective (male) subjects who are sexually active with female partners must agree to use condoms as well as one of the following highly effective (failure rate <1%) methods of contraception with their partner(s) from 14 days prior to the time of NEX-20A administration until 90 days after the follow-up/end-of-study visit (Visit 14).

• Previous male sterilization, defined as vasectomy conducted at least 6 months prior to screening with appropriate post-vasectomy documentation of the absence of sperm cells in the ejaculate.
• Previous female sterilization, defined as tubal ligation or permanent bilateral occlusion of fallopian tubes.
• Oral (except low-dose gestagen [lynestrenol and norethisterone]), injectable or implanted hormonal contraceptive associated with the inhibition of ovulation.
• Intrauterine device (IUD).
• Intrauterine hormone-releasing system (IUS), e.g., progestin-releasing coil

Exclusion Criteria:

1. Body weight outside body mass index 18-30 kg/m2

2. Subjects who intend to father a child during the course of the study, i.e., from screening to the final pregnancy check at Visit 15, or whose female partner is pregnant or currently breastfeeding.

3. Regular smoking or use of nicotine products within the past 6 months prior to screening. Irregular use of nicotine (e.g., smoking, snuffing, chewing tobacco) less than 3 times/week before the screening visit will be allowed.

4. Any intake of alcohol within the previous 24 hours of screening or subsequent study visits, according to alcohol urine tests.

5. Any positive screen for drugs of abuse at screening or subsequent study visits.

6. Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV), according to diagnostic tests.

7. Any use of prescription medication within the previous 14 days of the administration of NEX-20A, at the discretion of the Investigator.

8. Any use of over the counter (non-prescription) medication within the previous 48 hours of the administration of NEX-20A, at the discretion of the Investigator, except occasional intake of paracetamol (maximum 2000 mg/day), as well as nasal decongestants without cortisone, antihistamine or anticholinergics.

9. Regular use of any herbal remedies, vitamins, minerals, and other food supplements, at the discretion of the Investigator, within the previous 14 days of the administration of NEX-20A.

10. Malignancy within the past 5 years, with the exception of in situ removal of basal cell carcinoma.

11. Dermatological conditions, tattoos or large scars on the abdomen, thigh or upper arm which, in the opinion of the Investigator, may limit the evaluation of local tolerability.

12. History of or current thromboembolic disease, including but not limited to deep vein thrombosis (DVT) and other venous thromboembolisms, untreated hypertension and/or untreated hyperlipidaemia, as judged by the Investigator.

13. Family history of thromboembolic disease, specifically first-degree relative with history of or current thromboembolic disease (see exclusion criterion 12), as judged by the Investigator.

14. History of or current hematologic disorder, including but not limited to thrombocytopenia and/or neutropenia, as judged by the Investigator.

15. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to lenalidomide or drugs with a similar chemical structure or class or to any other ingredient of the formulation/vehicle.

16. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.

17. Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks prior to the treatment visit (Visit 2).

18. Any planned major surgery within the duration of the study.

19. After 10 minutes supine rest at the time of screening, any vital signs outside the

following ranges:

• Systolic blood pressure: <90 or >140 mmHg, or
• Diastolic blood pressure <50 or >90 mmHg, or
• Pulse <40 or >90 bpm

20. Prolonged QTcF (>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting ECG at the time of screening, as judged by the Investigator.

21. Bilirubin >25 µmol/L, alanine aminotransferase (ALT) >1.1 µkat/L, and/or aspartate aminotransferase (AST) >0.75 µkat/L at the time of screening (all values 1x upper limit of normal [ULN]).

22. Estimated glomerular filtration rate (eGFR) <80 mL/min/1.73 m2 (determined from plasma creatinine by the revised Lund-Malmö GFR estimating equation) at the time of screening.

23. Haemoglobin <130 g/L, absolute neutrophil count (ANC) <1.3x109/L, and/or platelet count <150x109/L at the time of screening.

24. History of or current alcohol abuse or excessive intake of alcohol, as judged by the Investigator.

25. History of or current drug abuse, as judged by the Investigator.

26. History of or current use of anabolic steroids, as judged by the Investigator.

27. Participation in any other clinical study and/or treatment with another investigational drug within 90 days of the treatment visit (Visit 2).

28. Plasma donation within 1 month of screening or blood donation (or corresponding blood loss) during the last 90 days prior to screening.

29. Lack of suitability for participation in the study, for any reason, in the opinion of the Investigator.

Related Conditions & MeSH terms

• Multiple Myeloma

Intervention

Drug:
• NEX-20A
Subcutaneous prolonged-release injection

Locations

Country	Name	City	State
Sweden	CTC Clinical Research Consultants AB	Uppsala

Sponsors (2)

Lead Sponsor	Collaborator
Nanexa AB	CTC Clinical Trial Consultants AB

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects with a clinical significant change from baseline in the systolic blood pressure at 36 days	Measured in mmHg after 10 minutes supine rest. Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the diastolic blood pressure at 36 days	Measured in mmHg after 10 minutes supine rest. Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the ECG parameter PQ/PR at 36 days	Measured in ms in supine position after 10 minutes of rest using an ECG machine. Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the ECG parameter QRS at 36 days	Measured in ms in supine position after 10 minutes of rest using an ECG machine. Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the ECG parameter QT at 36 days	Measured in ms in supine position after 10 minutes of rest using an ECG machine. Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the ECG parameter QTcF at 36 days	Measured in ms in supine position after 10 minutes of rest using an ECG machine. Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the haematology blood parameters measurements at 36 days	Blood samples for the analysis of haematology will be collected through venepuncture or an indwelling venous catheter. Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the clinical chemistry blood laboratory measurements at 36 days	Blood samples for the analysis of clinical chemistry parameters will be collected through venepuncture or an indwelling venous catheter. Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the coagulation parameters blood laboratory measurements at 36 days	Blood samples for the analysis of clinical coagulation parameters will be collected through venpuncture or an indwelling venous catheter. Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the physical examination of the head at 36 days	Physical examination including assessment of the head. Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the physical examination of eyes at 36 days	Physical examination including assessment of the eyes. Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the physical examination of the ears at 36 days	Physical examination including assessment of the ears.Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the physical examination of the nose at 36 days	Physical examination including assessment of the nose.Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the physical examination of the throat at 36 days	Physical examination including assessment of the throat. .Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the physical examination of the skin at 36 days	Physical examination including assessment of the skin. Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the physical examination of the thyroid at 36 days	Physical examination including assessment of the thyroid. Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the physical examination of neurological status at 36 days	Physical examination including neurological status. Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the physical examination of the lungs at 36 days	Physical examination of the lungs including percussion, inspection, palpation, and auscultation.Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the cardiovascular status of at 36 days	Physical examination including inspection, palpation, and auscultation of the heart. Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the physical examination of the abdomen at 36 days	Physical examination including assessments of the abdomen (liver and spleen). Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the physical examination of lymph nodes at 36 days	Physical examination including assessments of the lymph nodes. Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in the physical examination of extremitets at 36 days	Physical examination including assessments of the extremitets. Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with treatment-related adverse events a assessed by frequency	Number of events.Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with treatment-related adverse events a assessed by seriousness	Seriousness of adverse events.Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with treatment-related adverse events a assessed by intensity	Intensity of adverse events.Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in local tolerability i.e skin reactions assessed by visual inspection.	Visual inspection. Descriptive individual data.	From first dose until day 36
Primary	Number of subjects with a clinical significant change from baseline in local tolerability i.e skin reactions assessed by photography.	Photography of injection site. Descriptive individual data.	From first dose until day 36
Secondary	Maximum observed plasma concentration (Cmax)	Measurement of lenalidomid	pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
Secondary	Time of occurrence of Cmax (Tmax)	Measurement of lenalidomid	pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
Secondary	Area under the plasma concentration vs. time curve (AUC) from time 0 to 8 hours	Measurement of lenalidomid	pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
Secondary	AUC from time 0 to 12 hours	Measurement of lenalidomid	pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
Secondary	AUC from time 0 to 7 days	Measurement of lenalidomid	pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
Secondary	AUC from time 0 to infinity	Measurement of lenalidomid	pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
Secondary	Terminal elimination half-life	Measurement of lenalidomid	pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours